Disease · EFO_0010702
Trials157
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 20 of 157
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02510014 | Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder | Phase 3 | 775 | 2018-03-29 | Opioid Use Disorder, Opioid-related Disorders | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT02357901 | Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine | Phase 3 | 665 | 2018-02-20 | Opioid Dependence, Opioid Related Disorders | BUPRENORPHINE, NALOXONE | Its record names the disease | ClinicalTrials.gov |
| NCT02651584 | Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence | Phase 3 | 428 | 2019-08-22 | Opioid Use Disorders | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT02537574 | Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) | Phase 3 | 380 | 2019-01-09 | Opioid Use Disorder | BUPRENORPHINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT02672111 | Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder | Phase 3 | 228 | 2019-08-01 | Opioid Use Disorder | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT02334215 | A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail | Not applicable | 225 | 2020-09-16 | Opioid Use Disorder | METHADONE | Its record names the disease | ClinicalTrials.gov |
| NCT04470050 | Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal | Phase 1/2 | 225 | 2023-10-26 | Opioid Withdrawal | DEXMEDETOMIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT02896296 | Open-Label Treatment Extension Study | Phase 3 | 208 | 2018-11-02 | Opioid Use Disorder, Opioid-related Disorders | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT02110264 | Injectable Pharmacotherapy for Opioid Use Disorders (IPOD) | Phase 3 | 151 | 2020-01-22 | Opioid Use Disorders | NALTREXONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02617628 | Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone | Phase 2/3 | 146 | 2020-04-15 | Opiate Dependence | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT03275350 | Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up | Phase 2/3 | 114 | 2022-04-27 | Opioid-use Disorder, Hiv | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT03718065 | Impact of Lofexidine on Stress, Craving and Opioid Use | Phase 2 | 112 | 2025-02-07 | Opioid-use Disorder, Opiate Dependence | LOFEXIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT02696434 | Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL | Phase 3 | 101 | 2019-02-12 | Opioid Use Disorder | BUPRENORPHINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT03150173 | Onsite Buprenorphine Treatment at Syringe Exchange Programs | Phase 2 | 97 | 2025-01-14 | Opiate Addiction | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT04218240 | Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal | Phase 2 | 90 | 2024-05-20 | Opioid Withdrawal | LOFEXIDINE, PREGABALIN | Its record names the disease | ClinicalTrials.gov |
| NCT01587196 | CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery | Phase 2 | 72 | 2024-10-15 | Prescription Opiate/Medication Dependence | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT03248947 | Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075 | Early phase 1 | 71 | 2020-08-10 | Opioid Use Disorder | BUPRENORPHINE, NALOXONE | Its record names the disease | ClinicalTrials.gov |
| NCT02710526 | Phase II Pharmacokinetics Study of CAM2038 | Phase 2 | 66 | 2020-04-30 | Opioid Use Disorder, Chronic Pain | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT02611752 | A Multiple Dose Opioid Challenge Study | Phase 2 | 47 | 2019-11-14 | Moderate or Severe Opioid Use Disorder | BUPRENORPHINE | Its record names the disease | ClinicalTrials.gov |
| NCT03016598 | Stimulant Oxytocin Study | Phase 2 | 42 | 2021-06-10 | Stimulant Use & Co-occuring Opioid Use Disorders | OXYTOCIN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0010702/trials